News
As weight-loss injections like Mounjaro and Wegovy soar in popularity across the UK, jewellers say they’re seeing an unexpected side effect: wedding and engagement rings no longer fit, and in they are ...
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
TMates Weightloss Semaglutide reviews reveal how users are losing weight with this telehealth prescription service—see if it ...
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the head.
Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.
CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.
Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results